Shilpa Medicare jumped 4.33% to Rs 551.85 after the drug maker on Tuesday announced the launch of chronic constipation drug in adults.
The drug company launched PRUCALSHIL (Prucalopride), an orally disintegrating strips of 1 mg and 2 mg in India. Prucalopride is used for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief. Prucalopride medicine in the form of orally disintegrating strips and are most convenient dosage form for geriatric patients.Orally disintegrating strips have an advantage such as greater dissolution due to large surface area, more patient compliance than oral tablets, no risk of choking & better taste masking etc.
The company said it developed a novel 'Orally Disintegrating Strip (ODS)' formulation for Prucalopride and obtained subsequent approval from Drug Control General of India.
The launch of PRUCALSHIL will help Shilpa Medicare to build company's Gastro portfolio and going forward we are planning add more products in the Gastro basket.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.
On a consolidated basis, Shilpa Medicare's net profit slumped 56% to Rs 19.89 crore on 5.9% increase in net sales to Rs 295.27 crore in Q2 FY22 over Q2 FY21.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU